AEterna Zentaris
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, AEterna Zentaris sits in the top decile of US sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count).
AEterna Zentaris: 21 sponsored US clinical trials, none currently recruiting.
AEterna Zentaris sponsors 21 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 17 completed. 8 of these trials are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Benign Prostatic Hypertrophy, with 1 trials.
Top-decile sponsor footprint
AEterna Zentaris ranks in the top decile of sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
17 of 21 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
21 total, page 1 of 1
A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is
NCT04786873
Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
NCT02558829
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
NCT01767155
Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer
NCT01698281
A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies
NCT01224730
A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
NCT01234519
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
NCT01097018
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
NCT01002248
Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)
NCT00670306
Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
NCT00498966
Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test.
NCT00448747
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer
NCT00448721
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
NCT00449150
Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma
NCT00415064
A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia
NCT00398710
Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma
NCT00375791
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
NCT00398879
Phase I Trial of Paclitaxel With Perifosine
NCT00399126
Phase I Trial of Docetaxel With Perifosine
NCT00399087
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
NCT00399789
Phase I Perifosine and Gemcitabine Study
NCT00398697
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 6 |
| Phase 3 | 8 |
Therapeutic Areas
How the AEterna Zentaris early-phase archive is shaped
21 indexed studies, none listed as recruiting (0% open); 17 completed (81%).
Phase mix: 8 late (III/IV) vs 13 early (I/II) (early-phase heavy).
Top condition: Benign Prostatic Hypertrophy (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
AEterna Zentaris: archived-pipeline peers nationwide
Peers matched on 21 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
AEterna Zentaris sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 21 archived trials
- Amphastar Pharmaceuticals · 21 trials · 5% recruiting
- Apellis Pharmaceuticals · 21 trials · 10% recruiting
- Array Biopharma, now a wholly owned subsidiary of Pfizer · 21 trials · 0% recruiting
- Basilea Pharmaceutica · 21 trials · 14% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this AEterna Zentaris page
21 registered trials is a research-attention snapshot, not an endorsement of AEterna Zentaris or any single study.
- None of AEterna Zentaris's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Benign Prostatic Hypertrophy is the condition AEterna Zentaris studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Benign Prostatic Hypertrophy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
AEterna Zentaris pipeline card: 21 registered trials from official public datasets.Report a data error.